Pacemaker Market

Pacemaker Market Size, Share & Trends Analysis Report By Product (External, Implantable, Single Chamber Pacemakers, Dual Chamber Pacemakers, Cardiac Resynchronization Therapy-Pacemakers (CRT-P), By Application (Arrhythmias, Congestive Heart Failure), By End User, (Hospitals & Clinics, Ambulatory Surgery Centers and Others)By Region, And Segment Forecasts, 2019 – 2032

 

Pacemaker Market Size & Trends

In 2024, the global pacemaker industry was valued around USD 4.5 billion, and it is projected to develop at a CAGR of 5.5% during the period spanning between 2025 and 2030. There are several factors which drive market growth, including the increase in cardiovascular diseases, innovations in pacemaker design, and government financial and administrative support for regulating and reimbursement of pacemakers. According to the CDC in October 2024, a person will probably die due to cardiovascular disease every 33 seconds. Aging and growing heart conditions continue to expand the pacemaker-drawing pool, and technological advances such as leadless devices and remote monitoring increase patient outcomes. It encourages access to a great access into the market and thus the growth in developed and emerging regions.

Increased prevalence of cardiovascular disease (CVD) will continue to be the main growth driver for the pacemaker industry: primarily arrhythmia, followed by increased heart failures. As global populations grow older, heart conditions will increase and necessitate the employing of pacemakers, as it will supplement any cardiac interventions on irregular heart rhythms. CVD is a leading cause of disability and premature death in the European Region according to WHO by May 2024. It accounts for 42.5 percent plus of the total deaths each year, equal to almost 10,000 per day and caused mainly by organ failures associated with ischemic heart disease. Men die almost 2.5 times more often than women from CVD. Between age 30-69, the chance of dying as a result of a CVD is nearly five times higher in Eastern Europe and Central Asia than in Western Europe. Advances in diagnostics and increased awareness of heart health have also allowed for earlier detection and intervention, increasing pacemaker implantation demand.

These developments provide the patient more options for less invasive treatments that have longer battery life and better patient outcomes. Innovations such as the leadless pacemaker, an MRI-compatible device, and a rechargeable pacemaker enhance efficiency, reliability, and safety in devices. Integrating remote monitoring capabilities has propounded the market potential to personalize care and reduce hospital visits by tracking pacemaker function and heart rhythm in real time for healthcare professionals. Researchers at the University of Chicago created a wireless device that utilizes light to control cardiovascular or neural functions in the body in February 2024. These membranes that are now incredibly lightweight and thinner than a human hair can be implanted through minimally invasive surgery, and they have no movable parts.

Regulatory backup and proper reimbursement policies greatly affect the pacemaker industry. Many governments and health organizations continue to scale up their efforts toward improving access to advanced cardiac care by giving reimbursement for the pacemaker insertion procedure, making it easier for patients to obtain it. For example, in January 2024, Medtronic plc announced it had received the CE Mark for its latest-generation miniature, leadless pacemakers, the Micra AV2 and Micra VR2. According to the company, these devices, hailed as the world’s smallest, have an extended battery life and simpler programming when compared to their predecessors while offering all benefits of leadless pacing, such as decreased complication possibilities compared with conventional pacemakers.

Market Concentration and Characteristics

Since pacemakers are high-technology implantable devices, the level of innovation in the industry is extreme. Newer devices see continuous advances in miniaturization and battery life, remote monitoring systems, etc., to achieve a high degree of innovation. Current pacemakers are being made more patient-friendly and clinically beneficial by including features such as MRI compatibility, leadless designs, and wireless communication capabilities. These newly emerging technologies are presently making pacemakers safer, less invasive, simpler to use, and are continuing to be better researched for future biocompatible applications or improved algorithms for heart rhythm management.

Moderate levels of M&As characterize the pacemaker industry. There is some consolidation along the lines of big firms acquiring small companies for their technological capabilities or niche market offerings, but M&A activity remains relatively stable. Such companies as Medtronic, Abbott, and Boston Scientific are frequently found in strategic acquisitions to improve the product portfolio and increase market shares in areas such as new technologies like leadless pacemakers.

The regulation effect is severe in the pacemaker industry since the devices are hospital devices. The strict rules of regulation classify conditions for being critical on the grounds for medical intervention, where safety, effectiveness, and quality assurance are monitored by established regulatory authorities like the FDA, EMA, or other global health authorities. Such long regulatory approval processes take time, and even a slight modification of the guideline may significantly delay the product development timeline and market entry. Thus, compliance involves a major consideration for market players.

Currently, moderate levels of product expansion characterize the pacemaker industry owing to much emphasis given to improved leading pacemaker technologies. The new product innovations are still entering the field in innovations such as the leadless and the bioabsorbable pacemakers; hence, this continued stability should be expected without any major dynamics. It simply means that companies do not design totally new bands of pacemakers but only modify certain features such as battery life, device size, and remote monitoring capability.

Regional expansion in the pacemaker industry has been high in the developing regions like the Asia-Pacific, Latin America, and the Middle East where there is adequate demand for advanced cardiac care due to the larger pool of cardiovascular diseases and improving healthcare infrastructure. Companies actively pursue these regions using customized marketing strategies paired with affordable solutions and partnership agreements with local healthcare providers to leverage these emerging opportunities.

Regional Analysis

“High Adoption Pacemaker at the Back of Superior Health Facility Infrastructure and Awareness Among Patients”

The revenue generated by Europe in 2018 amounted to about US$ 1,500.1 Mn and is expected to be on top of the global cardiac pacemaker market during the entire forecast period. The existing developed healthcare infrastructure and awareness among the population in general are the primary factors propelling the speed of market expansion for pacemakers in Europe. Favorable regulation in reimbursement policy is creating an attractive opportunity for the growth of the pacemakers market in Europe and North America countries by 2026. Although emerging countries in Asia Pacific generate a lower share in the global market, cardiac pacemaker market in Asia Pacific is likely to observe a high CAGR as there is a rapid increase in the pool of patients with cardiac disorders. The rest of the world contributes a minor share in the global market since it remains less aware of this treatment and is deficient in trained healthcare professionals.

Insights into the Products

By product division, implantable pacemakers held the largest market share of 68.0% in 2024 and are set to exhibit the highest CAGR in the foreseeable future. An implantable pacemaker may be classified into two major groups: conventional and leadless. The conventional implantable pacemaker includes the following categories: single and biventricular and dual chamber. Whereas leadless are classified as either single or dual chamber. The increasing requirement of these devices to treat such diseases as heart failures and arrhythmias together with ongoing clinical trials is essentially a driving force which bolstered the market. In November 2024, an event dedicated to new developments in the industry of cardiac implantable electronic devices (CIEDs) was organized by HR24 (Heart Rhythm 24). The event highlighted device performance, longevity, and diagnostics advancements while addressing strategies to reduce complications and enhance patient outcomes.

Well proven in treating dramatic and progressive heart rhythm disorders, whether bradycardia (slow heart rate) or other conditions, implantable pacemakers have brought their fastest growth for their specific patient group. These devices tend to continually and reliably pace the heart and, thus, provide a much better outcome in terms of patient quality of life while avoiding consequences such as heart failure or stroke at a later stage. In August 2024, a publication in Circulation discussed a dual-chamber leadless pacemaker system assessing wireless atrioventricular synchrony. A multicenter trial, conducted with 384 patients, found that 98% of the beats were synchronous in differing activities and rates. Less failure to function and higher rates of successful implantation together with reliable performance at very high heart rates required for synchronizing pacing patients make this device superior to traditional pacemakers.

Application Insights

Bradycardia in 2024 accounted for a whopping 27.5% share in the market. Bradycardia mainly comprises the market because of its majority existence in the older sector of the population. The term bradycardia refers to the abnormal slowness of the heartbeat, usually less than 60 beats per minute; symptoms include feeling tired and dizzy and may jeopardize life. Therefore, the ultimate solution to manage this condition is the insertion of pacemakers into patients that would act as a rehabilitation device for a normalized heart function. According to an article by Circulation published in August 2024, male endurance skiers are observed to suffer more from bradycardia and pacemaker implants than nonskiers whereas this observation is not there in women. Among male athletes, those who raced most and had faster times had the highest rates of the two conditions.

Arrhythmias comprise the second largest component in the pacemaker market since these would imply the high incidence of abnormal heart rhythms that would need to be treated. Examples of these conditions include atrial fibrillation, ventricular arrhythmias, and other electrical conduction abnormalities that call for a pacemaker’s placement to restore normal heart function and lastly, in some cases, survival. So now that heart attacks are everywhere in the world, demand for pacemakers is never-ending. A June 2024 article indicated that atrial fibrillation (AF) is prevalent in pacemaker patients and that because of conduction blocks, pacing should not be concentrated on right atrial appendage but instead be done through interatrial septum (IAS) and Bachmann’s bundle pacing (BB). Moreover, another alternative may be that atrial ATP could hinder AF deterioration, and His bundle pacing might actually be a better site than conventional right ventricular pacing in preventing AF.

Usage Insights

In 2024, the hospital was anticipated to lead the income end-user segment, capturing a share of approximately 73.6%. Hospitals develop into a major area for pacemaker implantation and management, the reason for which is their provision of infrastructure, technology, and expertise for the management and implantation of pacemakers. In general, hospitals take patients through diagnosis to postsurgical surgical monitoring, as they are mainly the primary areas for conducting cardiac surgeries and interventions. In August 2024, HCA Florida Largo Hospital became the first hospital in Florida’s west coast to perform a dual chamber leadless pacemaker implant outside a clinical trial. It reduces the chances of infection significantly, thus perfectly suited for patients such as those receiving dialysis who do not have a suitable site for conventional pacemakers. The outpatient facilities segment is forecasted to be the fastest growing during the forecast period as a result of the growing trend for minimally invasive procedures, shorter recovery, and cheaper cost-effective treatments. Many of the pacemaker implantations, especially those using new technologies such as leadless pacemakers, may nowadays be done as an outpatient procedure, thus minimizing long hospital days. Outpatient care means patients can go straight home instead of staying at the hospital, thus giving more convenience and less healthcare cost to patients. In February 2024, HRS leaders met with CMS officials to discuss reimbursement issues regarding dual-chamber leadless pacemakers in the outpatient setting. They requested that CMS consider pass-through payment under the OPPS to ensure separate reimbursement until a permanent pricing model is established.

Regional Analysis

The North-American market for pacemakers was found to possess the major part of the share. This dominance was reported to be 43.4% in the year 2024. This was a fact mainly due to highly developed healthcare infrastructure as well as an improving aging population in the region. The same is typical of acceptance of wide new technologies, including leadless and MRI-compatible pacemakers.

The U.S. has been very strong and involved as extensive healthcare spending has also matched the need for yet supportive reimbursement policies as well as rapid technological advancement in the field. Refurbished and brand-new pacemakers were reported to be equal concerning safety and efficacy when research presented at the Scientific Sessions of the American Heart Association in November 2024 has shown.

Refurbished pacemakers are a robust clinical option for more than 300 patient subjects from seven countries. This might be regarded as a low-cost solution directed towards patients from low- and middle-income countries. Reusing pacemakers, however, is prohibited in the U.S.; they are permitted re-sterilization within the U.S., but only for export purposes.

Trends in Mexico’s Pacemaker Market

The U.S. pacemaker market in 2024 accounted for the maximum share in the North America region in the total revenue generation of the pacemaker industry. The increasing prevalence of cardiovascular diseases as well as adaptability to advanced technologies result in demand-driving forces within the U.S. The U.S. has a very advanced healthcare setup which allows easy assimilation of the new technologies, such as leadless pacemakers and devices having remote monitoring capabilities. UC San Diego Health, as of this February 2024, became the first health system in San Diego to implant an innovative dual chamber leadless pacemaker system for the treatment of arrhythmias. Approved by the FDA in July 2023, this device has become less invasive for the management of irregular heartbeats. Atrial fibrillation, the most common kind of arrhythmia, is expected to reach around 12.1 million people in this country alone by the year 2030.

The demand for a pacemaker in Europe

It is expected to increase significantly in the following years due to an increase in the number of cardiovascular diseases, especially for older patients. Some of the key contributing countries are Germany, France, and Italy, which are used to developed healthcare systems and rest assured to find advanced medical technologies. However, the pacemaker market in Europe is driven by the EU Medical Device Regulation (MDR), ensuring that all pacemakers are built around high safety and quality standards. Some innovations like leadless pacemakers and remote monitoring solutions are also drawing attention across the continent. MicroPort CRM announced its latest implantable pacemakers – ALIZEA, BOREA, and CELEA – with a new Left Bundle Branch Area Pacing (LBBAP) therapy for improved physiological pacing of the conduction system of the heart. Bluetooth connectivity will be available within very small devices measuring 11cc, featuring a durability of around 13 years in battery life, and sophisticated patient monitoring functionalities.

 

 

The growth of the UK pacemaker

In market by a healthy CAGR during the forecast period is primarily due to factors such as aging population and the rising incidence of heart conditions. Besides, it is majorly shaped by the presence of an NHS, which provides affordable access to pacemakers and thus makes possible widespread usage of such devices throughout the country. In September 2024, Abbott launched the AVEIR dual chamber leadless pacemaker system, claiming it to be world’s first for treating arrhythmias, in the UK. Today, more than 2 million people in the UK suffer from heart rhythm issues, and the new system enables direct communication in both heart chambers via leadless pacemakers.

 

The pacemaker industry is expected to grow in Germany

The strong healthcare system, high standards of medical care, and an aging population characterize the pacemaker market in Germany. In Europe, Germany is among the largest medical device markets offering a fair share of advanced pacemaker technologies along with a very good reimbursement system through public health insurance of the country. In the year 2023, an article on the website of Medizinische Hochschule Hannover stated that about 110,000 pacemakers are implanted yearly in Germany.

French pacemaker market

The ceremony will be held in the presence of eminent personalities including the French pacemaker market is expected to grow during the forecast period. In France, elder people are becoming increasingly afflicted by cardiovascular disease, causing growth in the pacemaker market throughout the country. France’s health care system is well developed. Public health insurance widely supports the access to pacemakers in that country. Besides, increased incidences of arrhythmia are boosting market growth. According to a CardioSignal by Precordior article published in December 2023, AFib affects over a million people in France, making it a major health issue in the country.

Asia-Pacific Pacemaker Market Trends

However, the report finds that, because of entry of key players and untapped available opportunities, the Asia Pacific pacemaker market is expected to achieve a much higher growth rate. It is projected to grow with a CAGR of 6.2% from 2025 to 2030. The region has been making substantial investments in healthcare improvement, particularly in Japan, China, and India, which include cardiovascular diagnosis and treatment facilities. As reported in an article of Interventional Cardiology, in October 2024, the first AVEIR VR leadless pacemaker implantation was reported in Kazakhstani patients. It involved five male patients who were aged between 14 and 77 and presented with a variety of symptoms and comorbidities. All the patients showed clinical improvement with no early complications and so there was no complication associated with this procedure; demonstrate core benefits of leadless pacing technology between patients and medical professionals.

China

The China pacemaker market is poised for positive growth during the forecast period. The pacemaker market in China is grown by an older population and increasing prevalence of cardiovascular diseases over time. The epidemic of cardiovascular disease in China is escalating with increased demand for solutions in monitoring arrhythmia. According to a data from the National Centerous Bureau Information reported in December 2023, China has a higher percentage of population suffering from CVDs, approximately 330 million have severe cases of CVDs. However, China has an emerging adoption of pacemakers due to building healthcare infrastructures and shift toward modern medical technology. The urban sectors are showing higher cases when compared to rural cases.

Japan

The pacemaker market in Japan will experience an increase in the forecast period. Japan is one of the wisest advanced countries when it comes to healthcare delivery systems, and the country’s pacemaker market is growing because of the old people with heart diseases. Japan has one of the fastest-aging populations in the world. As at September 2023, according to the World Economic Forum, almost one-third of the country’s total population is over 65 years of age, which counts around 36.23 million people. The Japanese market is famous for early adoption for all medical technologies, including leadless pacemakers and other advanced features such as remote monitoring.

India

Thus, the pacemaker market in India is developing at a fast pace and is believed to continue growing rapidly during this forecast period. Increased cardiovascular diseases and awareness of heart health have been mainly responsible for prompting the rapid growth of this industry’s pacemaker segment. This increased demand will be felt because of a large aging population, better access to healthcare services, especially in urban settings, and the increasing demand for pacemakers. On November 2024, in Kolkata, Manipal Hospital Dhakuria became the first hospital in East India to implant injectable pacemaker for a 65-year-old patient. This leadless device is inserted through a small catheter endoluminally and monitors the heart’s electrical activity continuously. It provides upgrade potential to a dual-chamber and Bluetooth-enabled remote monitoring and is much safer than the traditional pacemaker.

Adverse Pacemaker Market Trends in Latin America

Currently, the Latin American market for pacemakers is seeing a rapid increase due to the growing incidence of cardiovascular diseases, an aging population, and healthcare infrastructure improvements. Key companies, such as Nihon Kohden, are investing heavily in the arrhythmia market with regulations that favor them as some of the major growth factors expected for this market in Latin America during the forecast period. Reports from Nihon Kohden show double-digit growth in foreign sales in its first-half result in 2023 because of increased demand in Latin America and the U.S.

Brazil

According to the forecast period, Brazil has good potential for the pacemaker market growth. Brazil is the largest pacemaker market in Latin America, which gains maximum benefit from a large population and upcoming growing burden of cardiovascular disease. Initiatives boosting the care and outcomes of patients with CVD in Brazil were launched by the Brazilian government and various institutions in September 2023. An important example is the partnership between Mount Sinai and the Brazilian Clinical Research Institute to promote cardiovascular disease research and medical education.

Middle East And Africa Pacemaker Market Trends

As much promising as it sounds, the pacemaker market in the Middle East and Africa has become a reality for the near future. There is a trend in the developing market towards the demand for pacemaker devices due to the rise in cardiovascular diseases and burgeoning improvements in health care infrastructure in cities and small towns. Countries like the UAE, South Africa, and Egypt are adopting advanced pacemaker technologies, raising their investments in health care with the emerging trends for cardiac care. On March 2024, Medicalgorithmics expanded its operations in the Middle East by signing an agreement with the Canadian Cardiac Centre. This partnership is aimed at establishing a new cardiology center in the UAE focusing on heart arrhythmia diagnostics.

Saudi Arabia

The pacemaker market in Saudi Arabia over the forecast period is expected to grow. Saudi Arabia’s market is expanding as the country grapples with an increasing burden of cardiovascular diseases, partly due to lifestyle changes and an aging population. The growing prevalence of CVD is driving the market growth. According to an article published by BMC Cardiovascular Disorders in March 2024, the prevalence of CVD among individuals aged 15 & above in Saudi Arabia is 1.6%.

Kuwait

The pacemaker market of Kuwait is estimated to show growth over the review period. Kuwait has a small yet rapidly developing pacemaker market, primarily driven by an aging population coupled with the increasing number of patients suffering from various cardiovascular diseases. The health care system in the country allows granting universal health coverage to ensure access to all essential medical devices, including pacemakers. Patients have advanced technologies as far as health is concerned, and Kuwait is embracing new types of pacemakers such as MRI-compatible devices.

The Top Most Pacemaker Company Insights

Prominent firms are perceived in both their novel product offerings and technology ingress, which enables their customers to grow their market share and benefit from a wider product range. These companies have been making significant investments in infrastructure to save on costs as they develop, manufacture, and commercialize a high volume of drugs worldwide. In addition to expanding their presence globally, many companies participate in several strategic partnerships with distributors and other companies.

Key Pacemaker Companies:

The following are the leading companies in the pacemaker market. These companies collectively hold the largest market share and dictate industry trends.

• OSYPKA MEDICAL
• Boston Scientific Corporation
• Zoll Medical Corporation, an Asahi Kasei Group Company
• Medtronic
• BIOTRONIK SE & Co. KG
• MicroPort Scientific Corporation
• MEDICO S.R.L.
• Shree Pacetronix Ltd.
• Abbott
• OSCOR Inc
• Lepu Medical Technology (Beijing) Co., Ltd.

 

Emerging Developments

Boston Scientific Corporation announced on 1 September 2024 that it had received FDA approval to broaden the INGEVITY+ Pacing Leads indication for conduction system pacing (CSP) and as a left bundle branch area (LBBA) sensing device. This approach offers an alternative to traditional right ventricular pacing for symptomatic patients with bradycardia, as it aims to utilize the heart’s intrinsic electrical conduction system to improve ventricular synchrony and decrease the long-term risk of heart failure from conventional pacing methods.

Abbott announced CE Mark approval for its AVEIR dual chamber (DR) leadless pacemaker, the first such device for dual chamber treatment of abnormal heart rhythms, in June 2024. The system consists of two small devices-AVEIR AR for the right atrium and AVEIR VR for the right ventricle-that wirelessly communicate to deliver coordinated therapy. Each device is about one-tenth the size of a traditional pacemaker, providing a new treatment option for patients with cardiovascular conditions.

“March 2024 is the time when MicroPort CRM launched the ALIZEA pacemaker along with Bluetooth technology in the country. The new technology ushered into cardiac care with the very first implantation at PIH Health Downey Hospital. The ALIZEA system consists of fantastic new pacemaker that joins with VEGA pacing leads for real-time monitoring and management of heart rhythm.” This technology promotes remote patient monitoring, ensuring continuous care and timely intervention, thus improving the patient outcome and reducing the number of in-person follow-ups.

Report Coverage 

They help heal the heart that beats up or down, so regular cardiac pacemakers are essentially devices that possess two components-a lead which carries electric impulses to regularize heartbeat and a generator to control the pacemaker and hold information. The exponentially increasing prevalence of cardiac conditions is anticipated to extend enormous potential growth to the cardiac pacemakers market in 2026.

 

The report thus provides qualitative and quantitative insights into cardiac pacemaker industry trends and detailed analyses of cardiac pacemaker market size and growth rates across all possible segments in the market. These segments include product, end-users, and region.

The market segmentation on the basis of the product is single chamber pacemakers, dual chamber pacemakers, and CRT-P (cardiac resynchronization therapy pacemakers). The varied end users included in the report include hospitals & clinics, ambulatory surgery centers, and others. Geographically, the market is segmented into four major parts that are North America, Europe, Asia Pacific, and the rest of the World. Within these regions, countries group themselves according to which ones they belong to.

Along with this, the report analysis includes cardiac pacemaker market dynamics and competitive landscape. Some of the most important insights based on which report: prevalence of sudden cardiac arrests in key countries, technology advancement in cardiac pacemakers, recent industry developments such as merger and acquisitions, regulatory scenario in key countries, types of new product launch, reimbursement scenario and market scenario.

The global pacemaker market report segmentation

The study projects revenues at the global, regional, and country levels, forecasts them for 2018-2030, and conducts analysis on recent industry trends within each sub-segment. For this study, Grand View Research has segmented the global pacemaker market report into sections by product, application, end use and region:

• Product Outlook (Revenue, USD Million, 2018 – 2030)

• • External pacemakers

• • • Single Chamber

• • • Dual Chamber

• • Implantable pacemakers

• • • Conventional

• • • • Single Chamber

• • • • Dual Chamber

• • • • Biventricular Chamber

• • • Leadless

• • • • Single Chamber

• • • • Dual Chamber

• Application Outlook (Revenue, USD Million, 2018 – 2030)

• • Bradycardia

• • Acute Myocardial Infarction

• • Arrhythmias

• • • Atrial Fibrillation

• • • Heart Block

• • • Long QT Syndrome

• • Congestive Heart Failure

• • Others

• End use Outlook (Revenue, USD Million, 2018 – 2030)

• • Hospitals

• • Outpatient Facilities

• Regional Outlook (Revenue, USD Million, 2018 – 2030)

• • North America

• • • U.S.

• • • Canada

• • • Mexico

• • Europe

• • • UK

• • • Germany

• • • France

• • • Italy

• • • Spain

• • • Denmark

• • • Sweden

• • • Norway

• • Asia Pacific

• • • Japan

• • • China

• • • India

• • • South Korea

• • • Australia

• • • Thailand

• • Latin America

• • • Brazil

• • • Argentina

• • Middle East & Africa

• • • South Africa

• • • Saudi Arabia

• • • UAE

• • • Kuwait

 

Segmentation

 

ATTRIBUTE	DETAILS
By Product	·       Single Chamber Pacemakers ·       Dual Chamber Pacemakers ·       Cardiac Resynchronization Therapy-Pacemakers (CRT-P)
By End-user	·       Hospitals & Clinics ·       Ambulatory Surgery Centers and Others
By Geography	·       North America (USA and Canada) ·       Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe) ·       Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific) ·       Rest of the World

 

Important News in The Industry

The newly developed mobile applications, which transfer the data from pacemaker to concerned physician, have been approved by FDA in November 2015.

The REPLY CRT-P was announced to have been launched by Sorin group in the European market during July 2015. This newly introduced device has sleep apnea monitoring and physiological rate response for heart failure management.

Two February 2017 announcements stated the recent FDA approval of the much-awaited Assurity MRI pacemaker — the latest implant added in Abbott’s product portfolio for use in patients requiring pacemaker therapy with MRI examinations.

 

Frequently Asked Questions About This Report

What are the driving factors of the pacemaker market?

The growing prevalence of cardiovascular diseases (CVDs), advances in technology, and reimbursed implantation of pacemakers are already the primary driving forces in the pacemakers market-associated benefits.

List the key players of pacemaker market?

Some of the major names dominating the pacemakers market inds include Medtronic; BIOTRONIK, Inc.; Boston Scientific Corporation; Abbott; ZOLL Medical Corporation; MEDICO S.p.A.; Vitatron; Pacetronix; and Cordis, Inc.

Which segment accounted for largest pacemaker market share?

North America seized the lion’s share of the pacemakers market in 2024, ringing the bell for a cool 43.4% dive among global competitors. Its developed healthcare infrastructure, promising reimbursement structure, higher expenditure per capita, and greater awareness among the general populace regarding advanced technologies stand tall and out in the bragging rights of such captures.

What is pace maker market growth?

Global pacemaker market is expected to grow at a compound annual growth rate of 5.7% in 2025-2030 so as to reach USD 7.7 billion by 2030.